Art

J-GLOBAL ID：201702275396922480   Reference number：17A0925532

One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies -

日本人患者における1年間のエボロクマブ投与の有効性および安全性-オープンラベル拡大OSLER研究結果のプール解析-

Author (11)： Hirayama Atsushi (Division of Cardiology, Department of Medicine, Nihon University School of Medicine) ,  Yamashita Shizuya (Departments of Community Medicine and Cardiovascular Medicine, Osaka University Graduate School of Medicine) ,  Yamashita Shizuya (Rinku General Medical Center) ,  Inomata Hyoe (Amgen Astellas BioPharma K.K.) ,  Kassahun Helina (Amgen Inc.) ,  Cyrille Marcoli (Amgen Inc.) ,  Ruzza Andrea (Amgen Inc.) ,  Yoshida Masayuki (Life Science and Bioethics Research Center, Tokyo Medical and Dental University) ,  Kiyosue Arihiro (Department of Cardiovascular Medicine, The University of Tokyo Hospital) ,  Ma Yuhui (Amgen Inc.) ,  Teramoto Tamio (Teikyo Academic Research Center, Teikyo University)
Material： Circulation Journal  (Circ J)
Volume： 81  Issue： 7  Page： 1029-1035(J-STAGE)  Publication year： 2017 
JST Material Number： F0908A  ISSN： 1346-9843  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *monoclonal antibody ,...
Semi thesaurus term： *エボロクマブ

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0925532&from=J-GLOBAL&jstjournalNo=F0908A") }}

Author keywords (5)： Dyslipidemia ,  Hyperlipidemia ,  Lipid-lowering therapy ,  LDL-C ,  PCSK9 inhibition

JST classification (2)： Clinical application of drugs acting on lipid metabolism  (GW13050X) ,  Treatment for metabolic diseases,nutritional diseases.  (GD05030F)

Reference (20)：

• 1. Iso H. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb 2011; 18: 83-88.
• 2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
• 3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
• 4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-2397.
• 5. Teramoto T, Uno K, Miyoshi I, Khan I, Gorcyca K, Sanchez RJ, et al. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis 2016; 251: 248-254.

Terms in the title (9)： 日本人 ,  患者 ,  エボロクマブ ,  投与 ,  安全性 ,  ラベル ,  拡大 ,  研究 ,  解析